(PTx) announced findings from a post hoc analysis of the eNRGy trial (NCT02912949) evaluating treatment beyond progression with zenocutuzumab in patients with advanced neuregulin 1 fusion-positive ...

The search for effective and accessible therapies for diabetes continues to draw attention to medicinal plants with a long ...

Rasayana Therapeutics, a biotech targeting the gut’s connection to other organs, has slotted a new microbiome-boosting drug candidate into its pipeline. | In a deal with Theriva Biologics potentially ...

Theriva received a $300,000 upfront payment at signing and is eligible for up to $38M in development, regulatory, and sales milestones along ...

DENVER, Feb. 19, 2026 (GLOBE NEWSWIRE) -- U.S. equity markets are pointing modestly lower this Thursday morning. The focus remains on earnings season kickoff and any fresh Fed commentary, but today’s ...

Shares of Theriva Biologics rocketed 48.6% to $0.29 yesterday, after it reported the out-licensing of SYN-020, to Rasayana Therapeutics, a privately-held company targeting the gut-organ axis biology ...

Patients with IIMs who were AMA-M2 positive vs negative had a greater risk for cardiac involvement, though overall survival was similar between groups.

Theriva received a $300,000 upfront payment at signing and is eligible for up to $38M in development, regulatory, and sales milestones along with tiered single-digit royalties on net product sales - - ...

Ten percent complete response and rapid, durable antitumor activity reported with RYBREVANT FASPRO; results surpass current standards of care RARITAN, N.J., Feb. 19 ...

BREAKWATER trial Cohort 3 analysis demonstrated statistically significant and clinically meaningful improvement in ...

Johnson & Johnson today announced new results from the Phase 1b/2 OrigAMI-4 study showing that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination ...